Treatment utilizing psychedelic drug ibogaine significantly reduces opioid withdrawal and cravings
New scientific research provides more evidence that the psychedelic drug ibogaine can help treat opioid withdrawal and cravings. The new findings are reported in the Journal of Psychoactive Drugs.
Malcolm and his colleagues found ibogaine treatment was associated with significant reductions in opioid cravings and withdrawal symptoms. Most of the patients (78%) did not exhibit clinical signs of opioid withdrawal 48 hours after receiving ibogaine. “It seems that ibogaine can interrupt the underlying neurocircuitry of opioid use disorder while delivering a profound psychological experience that reinforces recovery efforts,” Malcolm explained to PsyPost. “In our study ibogaine appeared to be able to reduce both the physical signs and symptoms of opioid withdrawal as well as reduce cravings for opioids.” “This means that ibogaine may simultaneously address both physical and psychological aspects of opioid use disorder, whereas other therapeutic agents for opioid use disorders address either physical aspects through continued opioid dependence (methadone, buprenorphine) or psychological aspects of addiction like craving (naltrexone), but do not address both and cannot be used together.”
Original Article (Psypost):
Treatment utilizing psychedelic drug ibogaine significantly reduces opioid withdrawal and cravings
Artwork Fair Use: Peter Frank and the ECfES.org Public Lending Library
